Financial Information - The annual performance announcement pertains to the fiscal year ending December 31, 2025[3] - The company will suspend the transfer of shares registration on July 9 and July 10, 2026, to determine eligibility for the final dividend[4] - The record date for the final dividend eligibility is set for July 10, 2026[4] - The announcement clarifies that a special dividend mentioned earlier should be removed[4] Company Structure - The board of directors includes both executive and independent non-executive members[5] - The chairman of the company is Tsai Hoi Shan[5] - The company is incorporated in the Cayman Islands and trades under stock code 3933[2] Announcement Details - The company confirmed that there are no modifications to the other information in the annual performance announcement[5] - The announcement was made on March 31, 2026[5] - The company emphasizes the accuracy and completeness of the announcement's content[1]
联邦制药(03933) - 2025 - 年度业绩